Preface to precision dosing of targeted anti-cancer drugs

    Research output: Contribution to journalEditorial

    3 Citations (Scopus)
    37 Downloads (Pure)


    Small molecule protein kinase inhibitors (KIs) and anti-neoplastic monoclonal antibodies (mAbs) are rapidly expanding classes of non-cytotoxic or ‘targeted’ antineoplastic drugs that are effective at treating numerous malignancies, including previously difficult to treat forms of cancers. However, variability in disposition causes inter-individual variability in drug exposure that is inadequately addressed by the standard fixed-dose schedule of administration (1). Accordingly, precision dosing has great potential to maximise therapeutic response, minimise adverse drug reactions (ADRs), and improve cost-effectiveness of these expensive drugs...
    Original languageEnglish
    Pages (from-to)S1498-S1499
    Number of pages2
    JournalTranslational Cancer Research
    Issue numberS10
    Publication statusPublished - 1 Dec 2017


    • pharmacology
    • dosage
    • kinase inhibitors
    • monoclonal antibodies
    • antineoplastic drugs
    • cancer treatment


    Dive into the research topics of 'Preface to precision dosing of targeted anti-cancer drugs'. Together they form a unique fingerprint.

    Cite this